Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53

A Second Controversial Duchenne Approval For Company

 
• By Andrew McConaghie
  
FDAEntrance_1200x675
The approval went through the newly reorganized FDA Office of New Drugs
Scrip Podcast

Have you checked out Scrip podcast?

New episodes every Thursday.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip